Reeve J. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976;1:1035-8.
Reeve J. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980;280:1340-4.
Slovik DM. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986;1:377-81.
Hesch RD. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover. Klin Wochenschr 1988;66(19):976-84.
Hock JM. Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J Bone Miner Res 1989;4(3):449-58.
Reeve J. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. Bmj 1990;301:314-8.
Reeve J. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1991;1:162-70.
Bradbeer JN. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 1992;37:282-9.
Reeve J. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporos Int 1993;3 Suppl 1:199-203.
Delmas PD. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 1995;16(6):603-10.
Cheng PT. Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate. J Bone Miner Res 1995;10(1):119-26.
Sone T. A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Miner Electrolyte Metab 1995;21(1-3):232-5.
Boyce RW. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 1996;11:600-13.
Lindsay R. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
Hodsman AB. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620-8.
Lane NE. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33.
Cosman F. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13(6):1051-5.
Hirano T. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45.
Jerome CP. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 1999;25:301-9.
Roe EB. Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis - Results from a placebo-controlled randomized trial. J Bone Miner Res 1999;14:1019.
Cann CE. PTH effects in the femur: Envelope-specific responses by 3DQCT in postmenopausal women. J Bone Miner Res 1999;14:1020.
Fujita T. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 1999;9:296-306.
Kurland ES. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
Rittmaster RS. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34.
Lane NE. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000;15:944-51.
Hodsman AB. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 2000;27:311-8.
Roe EB. Parathyroid hormone (hPTH 1-34) and estrogen dramatically increases bone density in postmenopausal osteoporosis: A placebo-controlled randomized trial. Osteoporosis Int 2000;11:522.
Hunziker J. Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. J Dent Res 2000;79(6):1431-8.
Gasser JA. PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 2000;1(1):53-6.
Dempster DW. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.
Jerome CP. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 2001;28:150-9.
Mashiba T. Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001;28:538-47.
Bilezikian JP. Therapy of male osteoporosis with parathyroid hormone. Calcif Tissue Int 2001;69:248-51.
Cosman F. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925-31.
Neer RM. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
Burr DB. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16:157-65.
Arnaud CD. Two years of parathyroid hormone 1-34 and estrogen produce dramatic bone density increases in postmenopausal osteoporotic women that dissipate only slightly during a third year of treatment with estrogen alone: Results from a placebo- controlled randomized trial. Bone 2001;28:S77-S.
Reeve J. Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J Bone Miner Metab 2001;19:102-14.
Body JJ. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35.
Vahle JL. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21.
Miller E. A review of combination regimens for osteoporosis--prevention and treatment. Int J Fertil Womens Med 2002;47(5):198-204.
Black DM. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
Finkelstein JS. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26.
Jiang Y. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41.
Misof BM. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003;88:1150-6.
Orwoll ES. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
Zanchetta JR. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-43.
Shao JS. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003;278(50):50195-202.
Maalouf N. Osteoporosis: combination therapy for better or worse. J Musculoskelet Neuronal Interact 2003;3(2):141-7.
Ma YL. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003;144(5):2008-15.
Hodsman AB. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-20.
Kurland ES. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004;15(12):992-7.
Lindsay R. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164(18):2024-30.
Ettinger B. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19(5):745-51.
Lecart MP. Combination/sequential therapy in osteoporosis. Curr Osteoporos Rep 2004;2(4):123-30.
Cosman F. Therapeutic potential of parathyroid hormone. Curr Osteoporos Rep 2004;2(1):5-11.
Bauer DC. Combination and sequential therapy with PTH and bisphosphonates. J Musculoskelet Neuronal Interact 2004;4(4):407.
Doggrell SA. Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis? Expert Opin Pharmacother 2004;5(4):955-8.
Martin TJ. Does bone resorption inhibition affect the anabolic response to parathyroid hormone? Trends Endocrinol Metab 2004;15(2):49-50.
Carnevale V. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage? Clin Endocrinol (Oxf) 2004;60:81-6.
Deal C. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20(11):1905-11.
McClung MR. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165(15):1762-8.
Genant HK. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone 2005;37(2):170-4.
Arlot M. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20(7):1244-53.
Paschalis EP. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 2005;90(8):4644-9.
Onyia JE. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem 2005;95(2):403-18.
Poole KE. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 2005;5(6):612-7.
Bellido T. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146(11):4577-83.
Keller H. SOST is a target gene for PTH in bone. Bone 2005;37(2):148-58.
Ferrari SL. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. Endocrinology 2005;146(4):1854-62.
Cosman F. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353(6):566-75.
Hodsman AB. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26(5):688-703.
Black DM. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353(6):555-65.
Compston J. Recombinant parathyroid hormone in the management of osteoporosis. Calcif Tissue Int 2005;77(2):65-71.
Kaufman JM. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005;16(5):510-6.
Alkhiary YM. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005;87(4):731-41.
Miao D. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 2005;115(9):2402-11.
Shao JS. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005;115(5):1210-20.
Binkley N. Combination therapy for osteoporosis: considerations and controversy. Curr Rheumatol Rep 2005;7(1):61-5.
Prince R. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20(9):1507-13.
Dobnig H. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005;90(7):3970-7.
Garces C. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis. Maturitas 2006;54(1):47-54.
Bilezikian JP. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporos Rep 2006;4(1):5-13.
D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int Suppl 2006(102):S29-33.
Tashjian AH, Jr.. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006;21(3):354-65.
Ste-Marie LG. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 2006;21(2):283-91.
Oxlund H. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 2006.
Lindsay R. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006;21(3):366-73.
Hwang JS. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006;17(3):373-8.
Finkelstein JS. Effects Of Teriparatide, Alendronate, Or Both On Bone Turnover In Osteoporotic Men. J Clin Endocrinol Metab 2006.
Delmas PD. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006.
Cinamon U. Primary hyperparathyroidism and malignancy: "Studies by nature". Bone 2006.
Charopoulos I. Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab 2006;91(5):1748-53.
Bauer DC. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006;91(4):1370-5.
Ma YL. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006;21(6):855-64.
Lindsay R. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007;22(4):495-502.
Miller PD. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007;92(9):3535-41.
Kakar S. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007;22(12):1903-12.
Yu CT. Early callus formation in human hip fracture treated with internal fixation and teriparatide. J Rheumatol 2008;35(10):2082-3.
Cejka D. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008;8(9):1864-70.
Vahle JL. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 2008;23(12):2033-9.
Miller PD. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93(10):3785-93.
Anastasilakis AD. Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis. Endocr J 2008;55(3):613-6.
Chavassieux P. Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 2008;23(7):1076-83.
Wermers RA. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int 2008;19(7):1055-65.
Obermayer-Pietsch BM. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008;23(10):1591-600.
Dobnig H. Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated with Alendronate. J Bone Miner Res 2009.
Leder BZ. Effects Of Teriparatide Treatment And Discontinuation In Postmenopausal Women And Eugonadal Men With Osteoporosis. J Clin Endocrinol Metab 2009.
Graeff C. Improvements in Vertebral Body Strength under Teriparatide Treatment Assessed In Vivo by Finite Element Analysis: Results from the EUROFORS Study. J Bone Miner Res 2009.
Langdahl BL. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009.
Recker RR. Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women with Osteoporosis. J Bone Miner Res 2009.
Jobke B. Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res 2009;50(1):46-54.
Cosman F. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009;24(6):1110-5.
Eastell R. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009;24(4):726-36.
Lindsay R. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 2009;20(6):943-8.
Finkelstein JS. Effects of teriparatide re-treatment in osteoporotic men and women. J Clin Endocrinol Metab 2009.
1. Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. The Journal of clinical endocrinology and metabolism. 2018;103(8):2949-57. link
2. Tay D, Cremers S, Bilezikian JP. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. Br J Clin Pharmacol. 2018;84(2):252-67. link
3. Liu Y, Levack AE, Marty E, Or O, Samuels BP, Redko M, et al. Anabolic agents: what is beyond osteoporosis? Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2018;29(5):1009-22. link
4. Leder BZ. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy. Current osteoporosis reports. 2017;15(2):110-9. link
5. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, et al. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017;92(2):200-10. link
6. Martin TJ, Seeman E. Abaloparatide Is an Anabolic, but Does It Spare Resorption? Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017;32(1):11-6. link
7. Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone. 2016;97:314-9. link
8. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA : the journal of the American Medical Association. 2016;316(7):722-33. link
9. Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. The Journal of clinical endocrinology and metabolism. 2015;100(2):697-706. link
Updated 2/2/19
